Cel-Sci Sees Potential With AIDS Vaccine

3 February 1997

Cel-Sci Corp has revealed that in an animal model of human immunity, itsHGP-30 AIDS vaccine, which uses heteroconjugate technology, "confers high levels of protection against a different strain of HIV than the one from which HGP-30 is derived."

Heteroconjugate technology combines T cell binding ligands with disease-associated peptide antigens such as HGP-30, which "differs from other vaccines or immunogen candidates because it is a synthetic copy of a highly conserved part of the p17 core protein of the HIV virus," says the company.

HGP-30 has been tested in trials with 39 HIV-negative subjects and is currently in a separate study with 24 HIV-positive patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight